Trial Profile
A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bexarotene (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Acronyms BEAT-AD
- 02 Jun 2015 Status changed from active, no longer recruiting to completed.
- 04 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record..
- 30 May 2013 Planned end date changed from 1 Feb 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov record.